Impact Biomedical (IBO) Cost of Revenue (2025 - 2026)

Impact Biomedical's (IBO) quarterly Cost of Revenue came in at $1000.0 in Q3 2025, down 90.91% on a QoQ basis from $11000.0 in Q2 2025.

Impact Biomedical (IBO) Cost of Revenue (2025 - 2026) Analysis & Trends

Impact Biomedical (IBO) has 1 years of Cost of Revenue data on file, last reported at $1000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cost of Rev (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	489.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	360.70 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	145.00 Mn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	93.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	174.53 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	298.26 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	387.98 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	67.21 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Impact Biomedical	49.54 Mn	49.53 Mn	2,000.00	1,000.00

Download Data